GM viruses can treat brain tumors; Drug-eluting stent market to hit $6B by 2015;

> Genetically modified viruses engineered to destroy cancer cells might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor. Report

> The global market for drug-eluting stents is expected to reach $6 billion by 2015, according to a new report. Report

> Arrowhead Research Corp., based in Pasadena, Calif., has increased its investment in RNAi drug delivery company Calando Pharmaceuticals. According to a news release, Arrowhead has invested $1 million in Calando and converted approximately $8 million of Calando debt to Arrowhead into equity. Release

> TransPharma Medical has changed the name of its drug delivery system ViaDerm to ViaDor, which is a handheld electronic device that creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. News

> Drug delivery abstract of the week: Ultrasound-Mediated Transdermal Drug Delivery: Mechanisms, Scope, and Emerging Trends. Abstract

> Drug delivery patent application of the week: Compositions and methods for controlled delivery of inhibitory ribonucleic acids Patent application